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The characteristics of aristolochic acid nephropathy (AAN) are interstitial ﬁbrosis and atrophy of the proximal tubules, but with
no change in glomeruli. To investigate the eﬀects of AA on renal functions and the pharmacokinetics (PKs) of p-aminohippuric
acid (PAH) and inulin, New Zealand white rabbits were used in this study. The plasma concentrations of PAH and inulin were
determined by validated HPLC methods. After a single intravenous administrationof 0.5mg/kgaristolochicacid sodium (AANa),
rabbits exhibited mild to moderate nephrotoxicity on the 7th day. Signiﬁcant tubulointerstitial damage to kidney specimens
was found, but there were no remarkable glomerular changes. Clearance rates of PAH and inulin both signiﬁcantly decreased
in AANa-treated rabbits. In addition, there was a signiﬁcant correlation among the degree of tubulointerstitial changes and PK
parameters of PAH after AANa administration, but no correlation was noted with the PKs of inulin. With mild to moderate AAN
in rabbits, the renal plasma ﬂow signiﬁcantly decreased by 55%, and the glomerular ﬁltration rate also signiﬁcantly decreased by
85%. In conclusion, major renal lesions were found on proximal tubules after AANa administration. The PKs of PAH and inulin
signiﬁcantlychanged, and kidney functions, including the RPF and GFR, were reduced.
1.Introduction
Chinese herbs inducing nephrotoxicity were ﬁrst reported in
early1992byVanherweghemetal.[1],consistingoftwosim-
ilar cases of rapidly progressive ﬁbrosing interstitial nephritis
in young Belgian women who had followed the same
slimming regimen. The same herbal name found in the
slimming formulas (Stephanie tetrandra) had inadvertently
been replaced with Aristolochia fangchi [2]. Aristolochic
acids (AAs), the main compounds of species of Aristolochia
[3], have been shown to cause tumor induction and renal
toxicity in experimental and clinical studies [3–5]. Thus,
this renal disease is more appropriately called aristolochic
acid nephropathy (AAN). In Belgium [6], more than 100
patients with AAN were recorded, among which 30% had
moderate renal failure and 70% were treated by maintenance
dialysisorrenalgrafting,andsimilarcaseswerealsoobserved
throughouttheworld[7–12].In2001,theUSFoodandDrug
Administration (FDA) advised consumers to discontinue
using herbal products which contain AAs [13]. Despite
the actions of the FDA and regulatory agencies in other
countries, these products containing AAs and suspected to
contain AAs are still available on the internet [14].
Morphological features of AAN include extensive hy-
pocellularinterstitial ﬁbrosiswith atrophyandlossoftubules
and are predominantly located in the superﬁcial cortex [15,
16]. However, it is interesting to note that the glomerular
structure is not aﬀected [15, 16]. The kidneys play a key role
in eliminating xenobiotics. Factors that aﬀect the ability of
the kidneys to eliminate drugs may cause marked changes
in the pharmacokinetics (PKs) of compounds. In a previous
study, renal morphological ﬁndings, including damage to
the proximal tubules in rabbits after AANa treatment [17],
were similar to other experimental studies and reports from
human patients [5, 15, 16, 18, 19]. Renal lesions increase as
the AANa dose increases, and AAI and AAII show nonlinear
PK properties [17]. To investigate the eﬀects of AA on the
renal function of rabbits, the current study was performed
to assess the PKs of p-aminohippuric acid (PAH) and inulin
in 0.5mg/kg AANa-treated rabbits. The renal plasma ﬂow2 Advances in Pharmacological Sciences
(RPF) and the glomerular ﬁltration rate (GFR) were also in-
vestigated.
2.Materialsand Methods
2.1. Chemical Compounds. All chemicals were reagent grade,
and all solvents were HPLC grade. Aristolochic acid sodium
(AANa, containing 41% AAI and 56% AAII), p-amino-
benzoic acid potassium salt (≥99%), and p-aminohippuric
acid sodium salt were obtained from Sigma. Inulin was ob-
tained from Fluka.
2.2. Animal Study. The general physiology of rabbits is sim-
ilar to that of humans [19]. In addition, histopathological
features of the tissues of AAN of rabbits are similar to
those ofhumans. Therefore, male New Zealandwhite rabbits
(2.0∼3 . 0k g )w e r eu s e df o rt h i ss t u d y .B e f o r et h ee x p e r i m e n t ,
rabbits were starved for at least 12h, but water was given ad
libitum. Two groups of rabbits were iv-administrated with
20mg/kg of PAH (n = 10) and inulin (n = 10) before and
on the 7th day after a single intravenous dose of 0.5mg/kg
AANa administration. The data collected before AANa
administration is shown as control groups. Blood samples
were collected at 5, 10, 20, 30, 45, 60, and 90min and 2, 3,
4, and 6h after dosing. After blood sampling, rabbits were
sacriﬁced to obtain kidney specimens. In addition, 3 more
rabbits without AANa administration were used as control
group for histological examination. All animal experiments
conformed to institutional guidelines.
2.3. High-Performance Liquid Chromatography (HPLC). The
HPLC instrument consisted of a pump (Shimadzu LD-
10AD), UV-VIS detector (Shimadzu-10A), autoinjector
(Shimadzu SIL-9A), and integrator (Shimadzu C-R7A). A
Cosmosil 5C-18AR (5μm,4.6 × 250mm) column was used
to analyze PAH and inulin in plasma samples. The ﬂow
rate was set to 1.2mL/min, and the UV wavelength was
set to 290nm. The mobile phase for PAH consisted of 4%
acetonitrile and 0.3% tetramethylammonium chloride in
a 0.01M phosphate butter solution (pH 4.0). The mobile
phase for inulin was composed of 2.5% acetonitrile and
0.3% tetramethylammonium chloride ina 0.01M phosphate
butter solution (pH 2.9).
2.4. Quantitation of the Plasma Concentrations of PAH.
One hundred microliters of 1μg/mL p-aminobenzoic acid
(PABA) used as the internal standard with a 4.2% perchloric
acid solution was added to 200μL of a plasma sample
and then mixed and centrifuged at 13,000rpm for 5min.
The supernatant was transferred to another tube and then
supplemented with 200μL dichloromethane. The tubes were
vortexed and centrifuged at 13,000rpm for 5min again, and
the supernatant was transferred to another tube which con-
tained 200mg ammonium sulfate and 200μL ethyl acetate.
The tubes were vortexed and centrifuged at 13,000rpm for
5min once again, and then the supernatant was transferred
to another tube. After desiccation under nitrogen gas, the
sample was reconstituted with 200μLo ft h em o b i l ep h a s e ,
and50μLwasusedforHPLC.Theconcentrationrangeofthe
standard curve was 0.1∼30μg/mL. This analytical method
was validated according to the “Guidance of Bioanalytical
Method Validation.” [20] The respective retention times of
PAH and PABA were 4.4 and 10.3min, respectively, with
no signiﬁcant endogenous peak being coeluted in the cor-
responding chromatograms. The linear regression equation
of the standard curve was Y = 0.2615X +0 .0064 with a
correlation coeﬃcient of 0.9999. The limit of quantitation of
PAH was 0.1 μg/mL.
2.5. Quantitation of the Plasma Concentrations of Inulin.
One hundred microliters of 1μg/mL PABA as the internal
standard with 7% perchloric acid solution was added to
200μL of a plasma sample and then mixed and centri-
fuged at 13,000rpm for 5min. The supernatant was trans-
ferred to another tube and then supplemented with
200μL dichloromethane. After vortexing and centrifuging at
13,000rpm for 5min, this supernatant was transferred
to another tube and left in boiling water for 30min to
hydrolyze inulin to fructose and allow the fructose to
be converted to 5-(hydroxymethyl)-2-furaldehyde (HMF).
Then the samples were cooled in cold water for 5min and
transferred to another tube containing 200mg ammonium
sulfate and 200μL ethyl acetate. The tubes were vortexed and
centrifuged at 13,000rpm for 5min again. The supernatant
was transferred to another tube. After desiccation under
nitrogen gas, the sample was reconstituted with 200μLo f
t h em o b i l ep h a s e ,a n d5 0μLw a su s e df o rH P L C .T h ec o n -
centration range of the standard curve was 0.1∼30μg/mL.
This analytical method was validated according to the
“Guidance of Bioanalytical Method Validation.” [20]T h e
respective retention times of inulin and PABA were 8.6
and 11.7min with no signiﬁcant endogenous peak being
coeluted in the corresponding chromatograms. The linear
regression equationofthestandardcurvewasY = 0.1282X−
0.1386 with a correlation coeﬃcient of 0.9995. The limit of
quantitation of inulin was 5μg/mL.
2.6. Data Analysis and Statistics. The plasma concentration-
time data of PAH and inulin of the rabbits were entered into
the computer program, PKCALC [21], to obtain the initial
estimated parameters, and these were individually weighted
with another computer program, WinNonlin [22]. All of
the pharmacokinetic parameters, including the distribution
half-life(α-t1/2),eliminationhalf-life(β-t1/2),clearance(CL),
volume of the distribution at steady state (Vss), volume
of the distribution (V), volume of the distribution in the
central compartment (Vc), elimination rate constant of the
central compartment (k10), and the transfer rate constant
between the central and peripheral compartments (k12,k21),
were directly obtained from the WinNonlin output.The area
underthecurve(AUC)wasdeterminedusingthetrapezoidal
rule with the area from blood sampling time to inﬁnity
estimated as the last drug concentration divided by the
estimated terminal elimination rate constant, k.T h i sw a s
calculated by dividing 0.693 by β-t1/2.
RPFwascalculatedusingthePAHextractionratio(EPAH)
which was obtained from Gouyon and Guignard [23]v a l u e s
of 92.9%±1.9% observed in 29 normoxemic rabbits andAdvances in Pharmacological Sciences 3
of 90.0%±2.7% observed in 21 hypoxemic rabbits were
used. The other renal function parameters were calculated
with the following equations: ﬁltration fraction=GFR/RPF,
GFR=CLinulin,R P F =CLPAH/EPAH, and net secretion of
PAH = CLinulin − CLPAH [24, 25].
All data are expressed as the mean±SE. Statistical
signiﬁcance was determined by two-way analysis of variance
(ANOVA) for PK parameters.
2.7. Histological Examination. Blocks of renal tissues were
ﬁxed in 10% buﬀered formalin for a routine histological
examination. Because of minimal changes in the glomeruli,
the severity of renal changes was graded by the degree
of tubulointerstitial changes. Periodic acid-Schiﬀ-( P A S - )
stained sections were evaluated at a magniﬁcation of 100×,
and ﬁndings for the cortex were semiquantitatively scored.
The tubulointerstitial histological score was determined as
described by Sato et al. [18]. The scores used to evaluate
changes in the epithelial tubules were deﬁned as follows: 0,
no degeneration of the tubular epithelium; 1, one group or a
single degenerated tubule; 2, several clusters of degenerated
tubules; 3, moderate degenerationof the tubular epithelium;
4,moreseveredegenerationofthetubularepithelium;5,very
severe degeneration of the tubular epithelium, with massive
necrosis and atrophy present. Mononuclear cell inﬁltration
into the interstitium was evaluated by the following four-
p o i n ts c a l e :0 ,a b s e n t ;1 ,af e ws c a t t e r e dc e l l s ;2 ,g r o u p s
of mononuclear cells; 3, dense and widespread inﬁltration.
The existence of hyaline cylinders in distal tubules was
evaluated as follows: 0, absent and 1, cylinders present.
Interstitial ﬁbrosis was deﬁned as follows: 0, absent; 1, mildly
diﬀuse ﬁbrosis; 2, moderate ﬁbrosis; 3, severe ﬁbrosis. The
histological score of each rabbit was expressed as the sum of
these 4 scores. Nonparametric variables were analyzed by the
Mann-Whitney U-test. Statistically signiﬁcant diﬀerences
between groups were deﬁned at P<. 05.
3.Results
3.1. Pharmacokinetics of PAH. The plasma concentration-
time curves of PAH after a single iv-administrated dose of
0.5mg/kg AANa are shown in Figure 1.T h eP Kd a t ab e f o r e
and after AANa administration are given in Table 1.I tw a s
observed that after AA administration, CL (P = .010) and
k10 (P<. 001) were reduced by half. α-t1/2, β-t1/2,a n dA U C
signiﬁcantly increased (P<. 05). RPF was calculated using
EPAH which was obtained from the work by Gouyon and
Guignard [23]. In the control group, the EPAH was 92.9%
and RPF was 22.36±4.01mL/kg/min. Thus, in the group
administrated AANa, the extraction ratio was 90.0% and
the RPF was 10.11±2.72mL/kg/min, which signiﬁcantly
diﬀered from control rabbits (P<. 05).
3.2. Pharmacokinetics of Inulin. Table 2 shows the PK data of
inulin before and on the 7th day after 0.5mg/kg of AANa
iv administration. The plasma concentration-time curves
are shown in Figure 2.T h eC La n dk (P<. 001) sig-
niﬁcantly decreased, and the AUC signiﬁcantly increased.
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Figure 1: Plasma concentrations of p-aminohippuric acid (PAH)
after iv administration of 0.5mg/kg aristolochic acid sodium
(AANa) to rabbits (n = 10).
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Figure 2:Plasmaconcentrationsofinulin afterivadministrationof
0.5mg/kg aristolochic acid sodium (AANa) to rabbits (n = 10).
The GFR signiﬁcantly decreased from 5.95±1.79 to 0.89±
0.18mL/kg/min in the AAN group.
3.3. Renal Histological Findings after Administration of AANa.
On the 7th day after a single iv administration of 0.5mg/kg
AANa, rabbits were sacriﬁced to obtain renal specimens.
Moderate proximal tubular damage with 0.5mg/kg AANa
treatment was seen (Figure 3). The histological score in
the control included degeneration of tubular epithelium
(1.55±0.38), cell inﬁltration (0.49±0.39), and hyaline
cylinders (0.05±0.05), but interstitial ﬁbrosis was absent.4 Advances in Pharmacological Sciences
Table 1: Eﬀects of 0.5mg/kg aristolochic acid sodium (AANa) treatment on p-aminohippuric acid in rabbits (n = 10).
Control AANa treatment P value
CL (mL/kg/min) 20.77±3.73 9.10±2.45 .010
k10 (min
−1) 0.091±0.009 0.040±0.009 <.001
k12 (min
−1) 0.053±0.018 0.024±0.005 .104
k21 (min
−1) 0.057±0.008 0.039±0.009 .147
α-t1/2 (min) 5.41±1.10 10.85±2.22 .016
β-t1/2 (min) 25.09±3.25 94.28±28.56 .026
Vc (mL/kg) 228.72±30.38 246.09±36.84 .713
Vss (mL/kg) 404.26±51.28 509.32±165.07 .587
AUC (μg×min/mL) 1291.49±192.96 4376.83±1123.55 .017
∗Data are expressed as the mean±SE.
CL, clearance; k, elimination rate constant; k10, elimination rate constant of the central compartment; k12,k21, the transfer rate constant between the central
and peripheral compartments; α-t1/2, distribution half-life; β-t1/2, elimination half-life; V, volume of the distribution; Vc, volume of the distribution in the
central compartment; Vss, volume of the distribution at steady state; AUC, area under the curve.
Table 2: Eﬀects of 0.5mg/kg aristolochic acid sodium (AANa) treatment on inulin in rabbits (n = 10).
Control AANa treatment P value
CL (mL/kg/min) 5.95±1.79 0.89±0.18 .014
k (min
−1) 0.015±0.001 0.007±0.001 <.001
V (mL/kg) 452.42±173.38 130.91±10.90 .089
AUC (μg×min/mL) 4644.96±549.68 32246.76±6531.83 .002
∗Data are expressed as the mean±SE.
Parameters are described in the footnotes to Table 1.
1
3
2
Figure 3: Light microscopic ﬁndings of kidney specimens from
rabbits after treatment with 0.5mg/kg aristolochic acid sodium
(AANa). The renal histology changed 7 days after 0.5mg/kg AANa
iv administration. (PAS stain, magniﬁcation ×100). (1) Degener-
ation of tubular epithelium; (2) mononuclear cell inﬁltration; (3)
existence of hyaline cylinders.
However,afterAANatreatment onday7,thedegenerationof
the tubularepithelium (2.66±0.09, P<. 01), cell inﬁltration
(1.11±0.10), hyaline cylinders (0.78±0.06, P<. 05),
interstitial ﬁbrosis (0.49±0.11, P<. 05) were observed. The
sums of the histological scores on day 7 were 2.09±0.71 in
thecontroland5.03±0.23(P<. 01)inAANa-treatedrabbits
(Figure 4). Moreover, compare with the previous study [17],
there was no signiﬁcant diﬀerence in histological results
of 0.5mg/kg AANa-treated rabbits. Despite these tubular
changes, there was no remarkable glomerular change.
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Figure 4: Tubulointerstitial histological scores of rabbits after
treatment with 0.5mg/kg aristolochic acid sodium (AANa). ∗∗P<
.01.
4.Discussion
The pathology of AAN [15, 16] is characterized by a poor
ability for regeneration and a potent tendency towards
ﬁbrosis without glomerular injury. Thus far, renal plasma
ﬂow and glomerular ﬁltration changes in AAN have not
been evident. AAs can induce nephrotoxicity and tumor
toxicity in experimental studies [5, 18, 19], and the toxicity
o fA A si si r r e v e r s i b l e[ 26, 27]. In the present study, a single
iv administration of 0.5mg/kg AANa was chosen according
to a previous study [17]. On day 7 after administration ofAdvances in Pharmacological Sciences 5
AANa, the characteristic histological changes in rabbits were
mild to moderate degeneration of the tubular epithelium
and interstitial ﬁbrosis, and remarkable existence of hyaline
cylinders in distal tubules. The overall degree of nephrotoxic
eﬀects was mild to moderate, and the sum of the histological
score was 5.03±0.23, similar to the ﬁndings of a previous
study [17]. The experimental models of AAN were induced
by repeated doses, the histological ﬁndings of the proximal
tubules [5, 18, 19] were similar to those of this study, and no
alternation was found in glomerular capsules [18, 19].
PAH is cleared by both ﬁltration and secretion, and
thus has, been used to estimate RPF and the function of
renal anion secretion transporters (OATs) [24, 28]. Both
OAT1 and OAT3 [29–31], which mediate the transport
of PAH, are located in proximal tubules which exhibit
the main damage with AAN. The RPF with 20mg/kg
PAH in control rabbits showed no signiﬁcant diﬀerence
between this study (22.36±4.01mL/kg/min) and one by
Guignard et al. (13.66±1.83∼25.54±3.14mL/kg/min)[32–
35]. Some studies [36, 37] have reported that reductions in
theperitubularcapillary (PTC)densityand tubulointerstitial
ﬁbrosis area increased in AAN kidneys. Therefore, ischemia
and hypoxia occur in AAN, and this may contribute to
progressive tubulointerstitial ﬁbrosis. Thus, in the group
administrated AANa, the extraction ratio was 90.0% and
the RPF was 10.11±2.72mL/kg/min, which signiﬁcantly
diﬀered from those of control rabbits (P<. 05). The PK
data determined from the iv administration of AANa are
given in Table 1. When AAN was present, the results showed
signiﬁcant decreases in CL and k10 and signiﬁcant increases
in α-t1/2 and β-t1/2. Altered pharmacokinetic parameters
of PAH in AAN rabbits appear to be linked to several
factors: ﬁrst, the decreased RPF and the diminished delivery
of PAH to nephrons or renal tubules (22.36±4.01 versus
10.11±2.72mL/kg/min, P<. 05). Many PTCs in AAN
animals [36] and patients [37] are distorted and collapsed.
PTCinjury isconceivablyrelated toadecreased bloodsupply
to renal tubules [38]. Second, the GFR (5.95±1.79 versus
0.89±0.18mL/kg/min, P<. 05) and net secretion (14.82
versus 8.21mL/kg/min) also decrease PAH elimination.
Moreover, there was a close correlation between the degree
of tubulointerstitial changes and pharmacokinetic data of
PAH after AA administration; interstitial inﬁltration (r =
0.79,P<. 01); and overall tubulointerstitial lesions (r =
0.64,P<. 05) were positively correlated with the AUC, and
hyaline cylinders (r = 0.73,P<. 05) and interstitial ﬁbrosis
(r = 0.72,P<. 05) were negatively correlated with β1/2.T h e
net secretion decline inﬂuenced by interstitial inﬂammation
and ﬁbrosis in proximal tubulesaﬀected PK changes of PAH.
Inulin was used to measure the GRF. No signiﬁcant dif-
ference was seen in GFR at 5.95±1.79mL/kg/min in control
rabbits compared to reports by Guignard et al. [32, 33, 39]
and Pichette et al. [40] (3.69±0.37∼6.4±0.6mL/kg/min).
In this study, CL signiﬁcantly decreased by −85% and k
by −53%, while the AUC increased by 594% after AANa
treatment as shown in Table 2.H o w e v e r ,t h e r ew a sn o
correlation between the PK data for inulin in AANa-treated
rabbits and the degree of tubulointerstitial lesions. Inulin is
eliminated through the renal route only via ﬁltration, and
therefore tubulointerstitial lesions had no direct correlation
with the PKs of inulin. Although the glomerular structure
remained unchanged at the light microscopic level, levels of
GFR signiﬁcantly declined (P<. 05) in mild to moderate
AAN. The abrupt fall in the GFR may be associated with
aﬀerent vasoconstriction, transtubular backleak of the ﬁl-
trate, and interstitial inﬂammation. The characteristics of
AAN are extensive interstitial inﬂammation and ﬁbrosis
in the proximal tubules and increases in renal interstitial
pressure obstructing the reabsorption of isoosmotic ﬂuid
across the tubular epithelium. The ﬁltration fraction plays
a role in determining the tubular isoosmotic reabsorption
eﬃciency,particularly inproximaltubules[41].Inthisstudy,
a decreasing trend in the ﬁltration fraction from 27% to
4% represents net water reabsorption and reductions in
ﬁltrated solutes, such as sodium chloride and glucose. The
early development of normal glycemic glucosuria observed
in AANpatients [42] and in these AA-treatedanimals [5, 19]
might explain how the lesions in proximal tubules enhance
the passive tubular isoosmotic ﬁltrate backleak, while the
ﬁltration fraction decreases, in part, as an indication of
reduced proximal tubular sodium reabsorption leading to
an increased sodium chloride concentration and delivery to
themacula densa. This enhancedtubuloglomerularfeedback
sensitivity and renin secretion [43] as a consequence of
aﬀerent vasoconstriction lead to a fall in the GFR. Fur-
thermore, sodium reabsorption was constantly blocked with
the progression of disease, which also inﬂuenced water
reabsorption in the proximal tubules and then a decrease in
the volume of extracellular ﬂuid contraction. This inference
proves that a decrease in the distribution volume of inulin
was used as a measure of extracellular ﬂuid [44]. Then, a
decrease in the extracellular ﬂuid volume causes a decline
in the blood volume. The constriction of aﬀerent arterioles
may lead to decreases in both the GFR and the RPF through
a tubuloglomerular feedback mechanism. However, further
studies are needed to investigate these speculations.
In conclusion, mild to moderate nephrotoxicity was seen
on day 7 after a single administration of AANa. After AANa
administration, major renal lesions were found on proximal
tubules. The PKs of PAH and inulin signiﬁcantly changed,
and kidney functions, including the RPF and GFR, were
reduced. There was a signiﬁcant correlation between the
degree of tubulointerstitial changes and PK parameters of
PAH after AANa administration, but no correlation was
noted with the PKs of inulin.
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